ARTA
AGRX

A.R.T. Advisors’s Agile Therapeutics AGRX Stock Holding History

A.R.T. Advisors’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5
Closed -$28K – 290
2020
Q2 		$28K Buy
+5
New +$26K 0.04% 245
2018
Q2 		– Sell
-33
Closed -$170K – 1855
2018
Q1 		$170K Buy
33
+15
+83% +$99.2K 0.01% 1293
2017
Q4 		$97K Buy
18
+10
+125% +$93.1K ﹤0.01% 1259
2017
Q3 		$69K Sell
8
-5
-38% -$38.4K ﹤0.01% 1238
2017
Q2 		$97K Buy
+13
New +$90K 0.01% 1256

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
DCM
DG Capital Management New York $475M AUM 36.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

A.R.T. Advisors's AGRX Position: Q3 2020 in Review

A.R.T. Advisors sold out of Agile Therapeutics (AGRX) in Q3 2020, closing a stake of 5 shares — an estimated $28K sold.

A.R.T. Advisors first reported a position in AGRX in Q2 2017 and held it in 5 quarters. The position peaked at $170K in Q1 2018. 75 funds tracked by Wall St. Rank hold AGRX as of Q3 2020.

  • A.R.T. Advisors reported no remaining Agile Therapeutics position as of Q3 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 5 Agile Therapeutics shares in Q3 2020, an estimated $28K.
  • A.R.T. Advisors first reported a position in Agile Therapeutics in Q2 2017 and held it in 5 quarters.
  • A.R.T. Advisors's Agile Therapeutics position peaked at $170K in Q1 2018.
  • 75 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2020.

Based on A.R.T. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.